A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

Dosage forms containing nefopam, nefopam metabolite, nefopam prodrug, isomers thereof or combinations of the foregoing, optionally an acid, and optionally an opioid analgesic and/or NSAID, and associated methods for treating various types of pain in patients.

Dosage forms containing nefopam, nefopam metabolite, nefopam prodrug, isomers thereof or combinations of the foregoing, optionally an acid, and optionally an opioid analgesic and/or NSAID, and associated methods for treating various types of pain in patients.

A method for treating endometrial cancer comprising: administering to a patient a cannabis extract (CE) wherein the cannabis extract comprises cannabidiol (CBD) at between 50% and 99% by weight of the CE.

The present invention relates to a method of preparing a pharmaceutical composition comprising acetaminophen and nefopam, said method comprises in a first process step providing a wet granulated powder by mixing acetaminophen with one or more excipients; in a second process step adding nefopam and a lubricant to the granulated powder, and in a third process step, forming the pharmaceutical composition. Since the nefopam is added to the mixture in the second process step the impurities originating from nefopam is reduced to such an extend that said impurities cannot be detected in the final pharmaceutical composition using a conventional HPLC method.

The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies.

The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies.

The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents.

The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.

The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample.